New genetic variants could raise a woman’s risk of cervical cancer from HPV infections

Human papillomavirus (HPV) is the second most common cancer-causing virus, accounting for 690,000 cervical and other cancers each year worldwide.

Cybin Initiates First-in-Human Dosing of CYB004 in Phase 1 Clinical Trial | Psychedelic Finance

Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment

June 9, 2023

Transfer of operations of Reha-Klinik am Sendesaal to MEDICLIN took place on 1 May – Biotech Investments

EQS-News: MEDICLIN AG / Key word(s): Expansion/Contract MEDICLIN: Transfer of operations of Reha-Klinik am Sendesaal to MEDICLIN took place on 1 May 02.05.2024 / 17:14

May 3, 2024

Roche terminates a Phase 3 Spark gene therapy in hemophilia A

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

December 17, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.